By Christopher Weikart, PhD, Chief Scientist, SIO2 Materials Science
The primary container (e20191009_Biotech Drug Stability and Immunogenicity_Final-2x.
vial or syringe) needs to maintain the efficacy (prevent degradation)
of the drug throughout the shelf life. Biologic drugs are far more
prone to degradation compared to traditional small molecule drugs.
When a biologic drug experiences degradation and injected into
a patient, the body’s immune system can be triggered. This may
result in severe adverse drug reactions that may require that the
SiO2 Materials Science is a privately-owned U.S. advanced materials science corporation, involved in introducing breakthrough disruptive technology. While SiO2 was established in 2010, much of the core team has been working together since the 1950’s. The company is currently located in Auburn, Alabama close to Atlanta, Georgia and is in the process of developing a new facility located near Basel, Switzerland to manufacture the same six-sigma plus quality in all of its facilities. The company has deep partnerships with leading professors in the leading research universities such as University of California, University of Chicago, MIT, and CalTech.